CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy ...
Multikine (Leukocyte Interleukin, Injection) is CEL-SCI's flagship immunotherapy candidate. It is designed as a first-line treatment to be administered after diagnosis and before surgery, radiation, or chemotherapy, aiming to leverage the patient's intact immune system to combat tumors. It has undergone a large-scale Phase III clinical trial for the treatment of head and neck cancer.
Price Range: N/A (Clinical stage product)
Pain Points: High mortality rates in cancer patients; damage caused by standard surgery, radiation, and chemotherapy; need for effective immune-boosting treatments.
Solutions: Provides an immune-based therapy that may offer significant overall survival benefits without added toxicity, aiming to improve cancer treatment outcomes.
Target Users: Healthcare providers and patients diagnosed with primary head and neck cancer.
Supply Chain
Internal manufacturing facilitiesClinical research organizationsBiomedical material suppliers
A specific application of the LEAPS technology platform designed as a potential therapeutic intervention for H1N1-related infections.
Price Range: N/A (Research/Development)
Pain Points: Complications and mortality associated with viral respiratory infections.
Solutions: Enhanced immune response to specific influenza strains.
Target Users: Infectious disease patients.
Supply Chain
Internal R&DClinical research partners
Developed in collaboration with the University of Georgia's Center for Vaccines and Immunology, this therapy applies the LEAPS platform to target COVID-19 infection.
Price Range: N/A (Experimental)
Pain Points: Immune system failure in severe coronavirus cases.
Solutions: T-cell modulation to assist the body in fighting viral load.
Target Users: COVID-19 patients.
Supply Chain
University of Georgia (Partner)Internal R&D
Based on the LEAPS technology, this product is in development to specifically address the inflammatory processes involved in rheumatoid arthritis.
Price Range: N/A (Preclinical)
Pain Points: Pain, inflammation, and joint damage associated with rheumatoid arthritis.
Solutions: Specific immune modulation to dampen the autoimmune response.
Target Users: Rheumatoid arthritis patients.
Supply Chain
Internal R&D
A therapeutic candidate parallel to CEL-2000, developed to utilize the LEAPS technology to treat rheumatoid arthritis.
Price Range: N/A (Preclinical)
Pain Points: Chronic joint inflammation and autoimmune disease progression.
Solutions: Modulation of T-cell activity to reduce the progression of rheumatoid arthritis.
